PrimeRFP SCOUT · Federal Contract Recompete Brief

75N93023C00060SBIR PHASE II AWARD to VIA therapeutics — Via Therapeutics LLC

Via Therapeutics LLC holds $1.5M across 1 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 2 offers. Set-aside status: Unrestricted. PoP ended Sep 14, 2026 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

National Institutes Of Health Niaid

Awarding office

Via Therapeutics LLC

Recipient

Sep 14, 2026

PoP end

$1.5M

Obligated

$1.5M

Potential

541715

NAICS

AN12

PSC

Unrestricted

Set-aside

2 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Unrestricted

Contract number75N93023C00060

AgencyNational Institutes Of Health Niaid

Awarding officeNational Institutes Of Health Niaid

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentVia Therapeutics LLC

CAGE7CLS7

UEIYHRZATLXKL46

NAICS541715

PSCAN12

Place of performanceAUSTIN TX

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startSep 15, 2023

PoP end (current)Sep 14, 2026

Obligated$1.5M

Current value$1.5M

Potential value$1.5M

SBIR PHASE II AWARD TO VIA THERAPEUTICS is a federal Unrestricted award for National Institutes Of Health Niaid held by Via Therapeutics LLC. Estimated value $1.5M ($1.5M obligated). Current period of performance ends Sep 14, 2026. Last award drew 2 bidders. Place of performance: AUSTIN TX.

Recompete timing

Public

● Past PoP end (13 days ago)

Current PoP ended Sep 14, 2026 (13 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Bonuses end Sept 30

Want the durability read on 75N93023C00060? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Via Therapeutics LLC — $1.5M obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$1.5M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75N93023C00060?

75N93023C00060 (SBIR PHASE II AWARD to VIA therapeutics) is a National Institutes Of Health Niaid award with a potential value of $1.5M, currently held by Via Therapeutics LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N93023C00060?

National Institutes Of Health Niaid awarded 75N93023C00060 to Via Therapeutics LLC (potential $1.5M).

Who is the incumbent on 75N93023C00060?

Via Therapeutics LLC is the incumbent with $1.5M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Sep 14, 2026.

When does Via Therapeutics LLC’s 75N93023C00060 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 14, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 75N93023C00060? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jul 2, 2026 · refreshed monthlyLatest procurement action Sep 15, 2023